Latest & greatest articles for sumatriptan

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sumatriptan or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sumatriptan and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sumatriptan

1. Sumatriptan

Sumatriptan Top results for sumatriptan - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for sumatriptan The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

2. Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs Full Text available with Trip Pro

Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs Several sumatriptan subcutaneous autoinjector devices for acute treatment of migraine patients are available, each device differs with respect to design and features. Determining device preference and ease of use is important because patients experiencing a migraine attack are often functionally impaired.The objective of this human factors study was to compare migraine patients' device use (...) performance and preferences for three sumatriptan subcutaneous autoinjectors: a disposable two-step device (Zembrace® SymTouch®), a disposable three-step device (Sumavel® DosePro®), and a multistep reloadable device (Imitrex® STATdose®), using simulated injections.Each study subject performed two unaided simulated injections with each of three different drug delivery devices, which were presented in counterbalanced order. The participants were then asked to rate the three devices on various subjective

2017 Patient preference and adherence

3. Is Subcutaneous Sumatriptan an Effective Treatment For Adults Presenting to the Emergency Department With Acute Migraine Headache?

Is Subcutaneous Sumatriptan an Effective Treatment For Adults Presenting to the Emergency Department With Acute Migraine Headache? SystematicReviewSnapshot TAKE-HOME MESSAGE Subcutaneous sumatriptan provides effective treatment of migraine headaches, quickly eliminating pain and associated symptoms; however, it has yet to be proven as an optimal emergency department (ED) treatment modality because of inadequate evidence of effectiveness in this setting, increased self-limiting adverse events (...) with subcutaneous su- matriptan to treat a migraine headache episode. DATA EXTRACTION AND SYNTHESIS Two review authors indepen- dently extracted data. Disagree- ments were resolved with the help of a third author. Relative risk was calculated with a ?xed- effect model. Numbers needed to treat were estimated with the Cook and Sackett 1 method. The quality of evidence was assessed using the Oxford Quality Scale. Is Subcutaneous Sumatriptan an Effective Treatment for Adults Presenting to the Emergency Department

2013 Annals of Emergency Medicine Systematic Review Snapshots

4. Sumatriptan for the treatment of acute migraine attacks

Sumatriptan for the treatment of acute migraine attacks '); } else { document.write(' '); } ACE| Sumatriptan for the treatment of acute migraine attacks Search > > Sumatriptan for the treatment of acute migraine attacks - Sumatriptan for the treatment of acute migraine attacks Published on 3 May 2017 Guidance Recommendations Following an evaluation of sumatriptan for the treatment of acute migraine attacks, sumatriptan 50mg tablet is recommended for listing on the MOH Standard Drug List 2 (SDL2 (...) ) by the MOH Drug Advisory Committee in view of its clinically superior outcomes when used in combination with naproxen compared with either sumatriptan or naproxen monotherapy, and the low cost of subsidy. This recommendation means that subsidies will apply to sumatriptan for the indications registered in Singapore: Acute relief of migraine attacks with or without aura, including the acute treatment of migraine attacks associated with the menstrual period in women. Quicklinks | | | | | Copyrights © 2019

2017 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

5. I have a 67 year old female patient with migraines who has used oral sumatriptan for many years. She has tried many migraine treatments over the years but triptans are the only thing that work well fo

I have a 67 year old female patient with migraines who has used oral sumatriptan for many years. She has tried many migraine treatments over the years but triptans are the only thing that work well fo I have a 67 year old female patient with migraines who has used oral sumatriptan for many years. She has tried many migraine treatments over the years but triptans are the only thing that work well for her. The local pharmacist has told her she should no longer be using them. The BNF states use (...) across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com I have a 67 year old female patient with migraines who has used oral sumatriptan for many years. She has tried many migraine treatments over the years but triptans are the only thing that work well

2014 TRIP Answers

6. Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study

Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01986088 Recruitment Status : Completed First Posted : November 18, 2013 Last Update Posted : November 18, 2013 Sponsor

2013 Clinical Trials

7. Sumatriptan Galpharm

Sumatriptan Galpharm 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8545 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged London, 23 November 2011 EMA/40740/2012 Assessment Report Sumatriptan Galpharm 50 mg Tablets International non proprietary name: sumatriptan Procedure No. EMEA/H/C (...) /002140 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted Sumatriptan 50 mg Tablets Perrigo Assessment Report EMA/40740/2012 Page 2/43 Table of contents 1 3 Background information on the procedure 1.1 3 Submission of the dossier 1.2 5 Steps taken for the re-examination of the product 2 5 Scientific discussion 2.1 5 Introduction 2.2 6 Quality aspects 2.3 10 Non- Clinical aspects 2.4 11 Clinical Aspects 2.5 21 Pharmacovigilance 3 25 Benefit-Risk

2012 European Medicines Agency - EPARs

8. Bilateral Renal Infarctions During the Use of Sumatriptan Full Text available with Trip Pro

Bilateral Renal Infarctions During the Use of Sumatriptan 30197992 2019 02 26 2468-0249 3 5 2018 Sep Kidney international reports Kidney Int Rep Bilateral Renal Infarctions During the Use of Sumatriptan. 1233-1236 10.1016/j.ekir.2018.05.003 Abramovitz Blaise B Renal Electrolyte and Hypertension Division, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Leonberg-Yoo Amanda A Renal Electrolyte and Hypertension Division, Perelman School of Medicine

2018 Kidney international reports

9. WITHDRAWN: Oral sumatriptan for acute migraine. (Abstract)

WITHDRAWN: Oral sumatriptan for acute migraine. Migraine is a common neurovascular disorder characterized by recurrent episodes of disabling headache, autonomic nervous system dysfunction, and, in some patients, neurological aura symptoms. Sumatriptan is one of a class of selective serotonin 5-hydroxytryptamine (5-HT1B/1D) agonists (triptans) thought to relieve migraine attacks by several mechanisms, including cranial vasoconstriction and peripheral and central neural inhibition.To describe (...) and assess the evidence from randomized controlled trials (RCTs) concerning the efficacy and tolerability of oral sumatriptan for the treatment of a single acute attack of migraine in adults.We searched the Cochrane Central Register of Controlled Trials (Cochrane Library, Issue 4, 2001), MEDLINE (1966 through November 2001), and reference lists of articles and books.We included double-blind RCTs comparing oral sumatriptan (100 mg, 50 mg, 25 mg) with placebo, no intervention, other drug treatments

2012 Cochrane

10. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat

Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat Tfelt-Hansen P Authors (...) ' objectives To assess the efficacy, speed of onset and adverse events of sumatriptan given using various routes of administration for migraine treatment. Searching The author searched MEDLINE (over the entire date range, performed in April 1997), using the terms 'migraine', 'sumatriptan', and 'clinical trials'. Printouts from the database on clinical trials on sumatriptan were obtained from Glaxo Wellcome Denmark. The journals 'Archives of Neurology', 'Neurology', 'Headache' and 'Cepalalgia' from 1990

1998 DARE.

11. Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine

Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine Evans K W, Boan J A, Evans J L, Shuaib A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Oral drug therapy for migraine headache, specifically sumatriptan and caffeine/ergotamine. Type of intervention Treatment. Economic study type Cost-effectiveness, cost-utility and cost-benefit analyses were performed. Study population The study population was stated to be individuals aged 18-65 years, with moderate to severe migraine. Pregnant women

1997 NHS Economic Evaluation Database.

12. Intranasal sumatriptan for treatment of migraine: systematic review and meta-analysis study

Intranasal sumatriptan for treatment of migraine: systematic review and meta-analysis study Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2016 PROSPERO

13. Subcutaneous sumatriptan for the treatment of postcraniotomy pain (SUPS trial): protocol for a randomised double-blinded placebo controlled trial. Full Text available with Trip Pro

Subcutaneous sumatriptan for the treatment of postcraniotomy pain (SUPS trial): protocol for a randomised double-blinded placebo controlled trial. Postcraniotomy pain protocols use opioids, which are considered suboptimal analgesia following this procedure. Multimodal analgesia components are sparse. Our null hypothesis states that sumatriptan is not different to placebo in addition to usual intravenous opioids, for the treatment of acute postcraniotomy pain.This is a prospective single-centre (...) randomised double-blinded placebo-controlled phase III clinical trial comparing subcutaneous sumatriptan injection in the recovery area with placebo for the treatment of postcraniotomy pain. Eligible adult patients (18 years and older) undergoing craniotomy will be identified preoperatively. Both patient groups will receive a subcutaneous injection at a point where recovery-nursing staff would initiate the usual intravenous opioid analgesia as per standardised pain management protocol. In both groups

2019 BMJ open Controlled trial quality: predicted high

14. Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study Full Text available with Trip Pro

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study DFN-11, a 3 mg sumatriptan subcutaneous (SC) autoinjector for acute treatment of migraine, has not been assessed previously in multiple attacks. The objective of this study was to evaluate the efficacy, tolerability, and safety of DFN-11 in the acute treatment of multiple migraine attacks.This was an 8-week open-label extension of multicenter, randomized, double

2018 The journal of headache and pain Controlled trial quality: predicted high

15. Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the CO (Abstract)

Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the CO Fast relief of migraine pain, associated symptoms, and migraine-related disability are priorities in the acute treatment of migraine. Efforts to improve the pharmacokinetic profiles of acute migraine treatments with the aim of providing faster (...) relief include the development of non-oral routes of administration. AVP-825 (ONZETRA® Xsail® ) is a delivery system containing 22 mg sumatriptan powder that uses a patient's own breath to deliver medication intranasally, targeting the upper posterior nasal cavity beyond the narrow nasal valve, an area lined with vascular mucosa conducive to rapid drug absorption into the systemic circulation. While most studies comparing treatments measure differences in proportions of patients achieving

2017 Headache Controlled trial quality: uncertain

16. What is evidence, if any, for toxicity of sumatriptan in pregnancy.

What is evidence, if any, for toxicity of sumatriptan in pregnancy. What is evidence, if any, for toxicity of sumatriptan in pregnancy. - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search (...) information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com What is evidence, if any, for toxicity of sumatriptan in pregnancy. As with all question that relate the safety of medication use during pregnancy and breastfeeding, ATTRACT suggests GPs contact the National Teratology Information Service on 0191 232 1525

2009 TRIP Answers

17. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. (Abstract)

A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. Intranasal sumatriptan (Imitrex® ) may be an alternative for patients who refuse injections and cannot tolerate oral agents, but due to low bioavailability and slow absorption, the clinical utility of the currently marketed formulation is limited, highlighting an unmet need (...) for an effective non-oral migraine medication with a rapid onset of action. To overcome the slow absorption profile associated with intranasal administration, we evaluated the impact of 1-O-n-Dodecyl-β-D-Maltopyranoside (DDM, Intravail A-3™), a permeation enhancer, on sumatriptan's pharmacokinetic profile by comparing the pharmacokinetic characteristics of two commercial sumatriptan products, 4 mg subcutaneous and 6 mg subcutaneous in healthy adults, with DFN-02 - a novel intranasal agent comprised

2017 Headache Controlled trial quality: uncertain

18. Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo

Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01986270 Recruitment Status : Completed First Posted : November 18, 2013 Last Update Posted : November 18, 2013

2013 Clinical Trials

19. Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine

Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01248468 Recruitment Status : Completed First Posted : November 25, 2010

2010 Clinical Trials

20. Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache

Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Sumatriptan 4 mg (...) : Diamond Headache Clinic Collaborator: GlaxoSmithKline Information provided by: Diamond Headache Clinic Study Details Study Description Go to Brief Summary: This study's hypothesis is the 4mg StatDose sumatriptan is effective for the acute treatment of cluster headache and provides good safety and tolerability across multiple doses of the study medication as well as across multiple attacks of cluster headache. This study seeks to determine the safety and efficacy of the commercially available 4mg

2006 Clinical Trials